SRp30a Inhibitors

The chemicals listed above are characterized by their indirect inhibition of SRSF1 (SRp30a) through modulation of spliceosome function, primarily by targeting components of the SF3b complex. The SF3b complex is integral to the spliceosome, a cellular machinery responsible for removing introns from pre-mRNA and facilitating the correct assembly of exons to form mature mRNA. Inhibitors like Pladienolide B, Meayamycin, and E7107 exhibit high affinity for this complex, disrupting its normal function. This disruption leads to altered splicing patterns, which can indirectly influence the activity of SRSF1, a factor known for its role in constitutive and alternative splicing of pre-mRNA.

The majority of these compounds, including Sudemycin D6, FR901464, and Spliceostatin A, are found innatural sources or are synthetic analogs. Their mode of action involves binding to specific components of the SF3b complex, thereby hindering the complex's ability to accurately recognize splice sites. This misrecognition leads to aberrant splicing, which can have downstream effects on genes regulated by SRSF1. The indirect impact on SRSF1 is significant because of its role in the regulation of alternative splicing, a process vital for generating protein diversity and regulating gene expression in eukaryotic cells. Compounds like Herboxidiene and Madrasin further exemplify the diversity of chemical structures that can affect spliceosome function. In addition to these, drugs like Indisulam and Chloroquinoxaline Sulfonamide have shown an ability to alter splicing patterns, thereby providing a means to indirectly modulate the activity of SRSF1.